drugset / Trial / NCT05039658
Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether treatment with IBI110 single agent and in combination with sintilimab demonstrates sufficient efficacy/safety in r/r DLBCL.
Timeline
- Start
- 2021-09-27
- Primary completion
- 2022-07-12
- Completion
- 2022-12-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NEGALSTOBART | Monoclonal antibody | — | — |
| Subject | Sintilimab | Monoclonal antibody | — | — |